AlzeCure highlighted in a report on Parkinson’s and Alzheimer’s

A new report from Invest Stockholm conducts a review of knowledge about neurodegenerative diseases such as Parkinson’s and Alzheimer’s. Both the region’s academic research and selected companies are presented here.

The report highlights one of Flemingsberg’s knowledge companies: AlzeCure. Here, the company’s CEO Martin Jönsson talks about the development of new treatments for Alzheimer’s disease.

It is estimated that the number of people with dementia will increase from 50 million today to 150 million in 2050. Alzheimer’s disease is the most common form of dementia and is a major cause of disability and dependency among old people worldwide. Parkinson’s disease is the second most common age-related neurodegenerative disorder and can also have a devastating impact on quality of life.

Universities and research institutes in the greater Stockholm region are carrying out vital research into these diseases, which will help to achieve early diagnosis and reduce the impact of neurodegenerative conditions on people’s lives.

Read the new report from Invest Stockholm: Improving Quality of Life for People with Neurodegenerative Diseases

Photo: Anna Hugosson, mediabank.visitstockholm.com

Biosfär wins this year’s Flemingsberg Science Award

Biosfär is the winner of this year’s Flemingsberg Science Award, a company that wants to give nursing and care home residents the opportunity to experience different activities in virtual reality. The award was presented during the announcement of Venture Cup’s Digital Top20.

Load More Posts

Vill du veta mer?
Prenumerera på vårt nyhetsbrev.

PRENUMERERA

Vill du veta mer?
Prenumerera på vårt nyhetsbrev.

PRENUMERERA
CF_logo_neg
2021-02-09T16:36:09+01:00
Go to Top